Search research articles
Contact Us
Filters
Showing results (131-140 of 146) with videos related to
Page
of 15
Sort By:
Journal of Hepatology
|
September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Gregory J Dore, Brian Conway, Yan Luo, et al.
Annals of Internal Medicine
|
August 8, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study
Jason Grebely, Gregory J Dore, Frederick L Altice, et al.
HIV Medicine
|
October 2, 2023
Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV
Katia Giguère, Carl Chartrand-Lefebvre, Jean-Guy Baril, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 13, 2019
Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs
Sarah M Zaidan, Louise Leyre, Rémi Bunet, et al.
Annals of Internal Medicine
|
August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial
Gregory J Dore, Frederick Altice, Alain H Litwin, et al.
Advances in Therapy
|
October 29, 2024
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis
Markus Cornberg, Dietrich Hüppe, Christoph Sarrazin, et al.
JAMA
|
May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
Fred Poordad, William Sievert, Lindsay Mollison, et al.
The International Journal on Drug Policy
|
June 24, 2025
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C study
Joshua Ang, Behzad Hajarizadeh, Shane Tillakeratne, et al.
The International Journal on Drug Policy
|
November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Jason Grebely, Brian Conway, Evan B Cunningham, et al.
The International Journal on Drug Policy
|
October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study
Evan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 146) with videos related to
Sort By:
Page
of 15
Journal of Hepatology
|
September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Gregory J Dore, Brian Conway, Yan Luo, et al.
Annals of Internal Medicine
|
August 8, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study
Jason Grebely, Gregory J Dore, Frederick L Altice, et al.
HIV Medicine
|
October 2, 2023
Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV
Katia Giguère, Carl Chartrand-Lefebvre, Jean-Guy Baril, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 13, 2019
Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs
Sarah M Zaidan, Louise Leyre, Rémi Bunet, et al.
Annals of Internal Medicine
|
August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial
Gregory J Dore, Frederick Altice, Alain H Litwin, et al.
Advances in Therapy
|
October 29, 2024
Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis
Markus Cornberg, Dietrich Hüppe, Christoph Sarrazin, et al.
JAMA
|
May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
Fred Poordad, William Sievert, Lindsay Mollison, et al.
The International Journal on Drug Policy
|
June 24, 2025
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C study
Joshua Ang, Behzad Hajarizadeh, Shane Tillakeratne, et al.
The International Journal on Drug Policy
|
November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Jason Grebely, Brian Conway, Evan B Cunningham, et al.
The International Journal on Drug Policy
|
October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study
Evan B Cunningham, Janaki Amin, Jordan J Feld, et al.
Page
of 15